Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
Medication-assisted treatment (MAT) is the use of medications, combined with counseling, to treat substance use disorders. Research has proven the effectiveness of MAT and addiction treatment experts endorse it, but a variety of barriers have prevented the widespread use of MAT. These include a lack of financing for medication, insufficient organizational infrastructure to deliver medication, state and county funding and regulatory obstacles, physician training and certification, staff and client resistance, and community attitudes.
Posted 5/3/2021 (updated 4/10/2024)
Building on Part I of the stigma webinar series and its introduction of a statewide collective impact model for addressing stigma, this webinar delivered the first part of the model that also served as its conceptual framework. This webinar introduced the stages of change and showed grantees how these apply to their target populations. We also discussed how those same principles applied to grantee engagement of community stakeholders and their openness to evidence-based practices that reduce morbidity and mortality related to SUD/OUD.
Posted 7/7/2021 (updated 4/2/2024)
This Technical Briefing provides a description of Peer-to-Peer Distribution of Naloxone (P2PN). This is based on six case studies of pioneers of P2PN; three from the UK and three international examples that inform the guidance in this Technical Briefing. This document will inform and be extended following a pilot of P2PN in four sites in England in 2019. These will be supported by small grants from EuroNPUD. The learning from this pilot will help test the model and peer education approach promoted in this briefing.
Posted 11/21/2019 (updated 3/28/2024)
The New York State Department of Health (NYSDOH) convened a Technical Working Group on Resuscitation Training in Naloxone Programs to ensure that overdose programs in New York State (NYS) and elsewhere are afforded the best possible resuscitation protocol guidance tailored to suspected opioid overdoses in diverse settings.
Posted 11/19/2019 (updated 3/28/2024)
This guidance document is intended to support the development of comprehensive prevention. Work Plans that are based on local data and designed to achieve measurable outcomes.
Posted 8/24/2020 (updated 3/28/2024)
Syringe service programs (SSPs), which provide access to sterile syringes and other injection equipment and their safe disposal after use,* represent a highly successful human immunodeficiency virus (HIV) prevention intervention. SSPs are associated with a 58% reduction in the incidence of HIV infection among persons who inject drugs. In addition, SSPs have led efforts to prevent opioid overdose deaths by integrating evidence-based opioid overdose education and naloxone distribution (OEND) programs. OEND programs train laypersons to respond during overdose events and provide access to naloxone and directions for drug delivery. SSPs are ideal places for OEND because they provide culturally relevant services designed to reach persons at high risk for experiencing or observing an opioid overdose.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 7/27/2020 (updated 3/28/2024)
The American Medical Association’s Opioid Task Force report shows a dramatic increase in fatalities involving illicit opioids, stimulants (e.g. methamphetamine), heroin and cocaine and a similarly dramatic drop in the use of prescription opioids.
Posted 9/14/2022 (updated 3/27/2024)
The Reagan-Udall Foundation for the FDA (FDA Foundation), in partnership with several operating divisions within the Department of Health and Human Services (HHS), convened two roundtable meetings to understand the perspectives of the harm reduction community, clinicians, and researchers about using fentanyl drug checking and screening as harm reduction and clinical strategies.